Skip to content

A Randomized Controlled Clinical Study of Kuanxiong Aerosol on Coronary Heart Disease combined with Depression

A Randomized Controlled Clinical Study of Kuanxiong Aerosol on Coronary Heart Disease combined with Depression

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074390
Enrollment
Unknown
Registered
2023-08-04
Start date
2023-07-24
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease combined with depression

Interventions

Control group :Conventional Western Medicine+Shugan Jieyu capsules
Experimental group :conventional Western medicine+Kuanxiong aerosol

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? 18 = Age<65 years old; ? Meets the diagnostic criteria of Western medicine for coronary heart disease and angina pectoris; The frequency of angina attacks in the first week before inclusion is = 3; ? Conforming to the diagnostic criteria for depression in the 2020 Consensus of Experts on the Integrated Diagnosis and Treatment of Depression with Traditional Chinese and Western Medicine; ? No antibiotics, Prokinetic agent or microecological regulators were used within 1 month; ? HAMA scores between 14 and 29 points and/or HAMD scores between 17 and 35 points; ? Sign an informed consent form;

Exclusion criteria

Exclusion criteria: ? Those with severe depression and anxiety who are difficult to cooperate; ? Cardiovascular diseases such as serious arrhythmia; ? Anxiety and depression secondary to other mental or physiological diseases; ? Bipolar affective disorder, intractable depression (two or more Antidepressant with different chemical structures are used, which are ineffective or have little effect after sufficient treatment); ? Patients with severe diseases of other systems, as well as severe heart, liver, and kidney dysfunction; ? Those who have taken antidepressant and anti anxiety Western medicine within one month before enrollment; ? Pregnant, lactating or urine Pregnancy test positive; ? Drug or alcohol addicts; Gender and race are not limited; All patients voluntarily sign an informed consent form.

Design outcomes

Primary

MeasureTime frame
Efficacy indicators for angina pectoris ;HAMD(24 items) ;Traditional Chinese Medicine Syndrome Points ;

Countries

China

Contacts

Public ContactYan Kuipo

Heart Center of the First Affiliated Hospital of Henan University of Chinese Medicine

ykp19821122@163.com+86 135 9889 8276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026